Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743611 · ClinicalTrials.gov registry record · Phase 1
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
A Phase 1 study, sponsored by Bellicum Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02743611: Clinical Trial Phase 1 study, sponsored by Bellicum Pharmaceuticals.
NCT02743611 is a Phase 1 study that was terminated before completion, run by Bellicum Pharmaceuticals. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02743611, a Phase 1 study, was terminated before completion, sponsored by Bellicum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.
Primary Outcome
Incidence of dose limiting-toxicity (DLT)
Interventions
- DRUG Rimiducid
- BIOLOGICAL BPX-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-04-14 |
| Est. Completion | 2020-07-19 |
| Phase | Phase 1 |
Why NCT02743611 stopped before completion
NCT02743611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Rimiducid is the first listed.
NCT02743611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02743611 about?
NCT02743611 is a clinical study titled "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma". The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and targ...
What is the current status of trial NCT02743611?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-04-14. Estimated completion is 2020-07-19.
What interventions are being tested in trial NCT02743611?
The interventions under investigation include: Rimiducid (DRUG), BPX-701 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02743611?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02743611's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI